Bangkaxin®Esomeprazole Magnesium Enteric-coated Tablets
Bangkaxin® Esomeprazole Magnesium Enteric-coated Tablets are a new generation of proton pump inhibitors (PPIs), approved as a Class 4 chemical drug. It is the only esomeprazole magnesium enteric-coated tablet in China that is bioequivalent to the original brand. It is clinically used for the prevention and treatment of acid-related diseases such as gastroesophageal reflux disease (GERD), peptic ulcers, stress ulcers, Helicobacter pylori eradication, and drug-induced gastric mucosal injury. It is widely used in clinical practice and is a first-line choice for acid suppression therapy and ulcer prevention and treatment.
Xiyanping Injection
Xiyanping Injection is a traditional Chinese medicine injection made from total sulfated andrographolide, a key component of Andrographis paniculata. It is part of the National “12th Five-Year Plan” Major Innovative Drug Discovery Project.
Weibiai® Roxadustat Capsules
Roxadustat is the world’s first oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) and is indicated for the treatment of anemia caused by chronic kidney disease (CKD), including both dialysis and non-dialysis patients.
Shuxinqing®Beraprost Sodium Tablets
Beraprost sodium works by activating prostacyclin receptors on platelets and vascular smooth muscle cells, which in turn stimulates adenylate cyclase, raises intracellular cAMP levels, inhibits calcium influx, and reduces thromboxane A2 production.
Zebixin® Mirabegron Sustained-release Tablets
Mirabegron is the world's first β3-adrenoceptor agonist approved for treating overactive bladder (OAB) in adults.
Ningqingtuo® Nifedipine Extended-Release Tablets
Ningqingtuo® Nifedipine Extended-Release Tablets are dihydropyridine calcium channel blockers, indicated for the treatment of hypertension, coronary artery disease, and stable chronic angina (exertional angina).
Ningqingtan® Acetylcysteine Effervescent Tablets
Ningqingtan® Acetylcysteine Effervescent Tablets are indicated for the treatment of chronic obstructive pulmonary disease (COPD), chronic bronchitis (CB), emphysema (PE), and other chronic respiratory diseases characterized by excessive and thick mucus secretion.
Zesuoxin® Tamsulosin Hydrochloride Sustained Release Capsules
Benign Prostatic Hyperplasia (BPH) is the most common cause of urinary disorders in middle-aged and elderly men. Tamsulosin hydrochloride is a highly selective α-adrenergic receptor inhibitor, with an affinity for α1 receptors that is 5,400 to 24,000 times stronger than its affinity for α2 receptors. It is 13 times more effective in inhibiting increased urethral pressure than it is in inhibiting vascular dilatation pressure. It is suitable for moderate to severe lower urinary tract obstruction. The short-term goal is to relieve the patient's lower urinary tract symptoms, while the long-term goal is to delay the clinical progression of the disease.